News in brief: Three lymphoma drugs for PBAC consideration; Warnings on Zostavax for immunosuppressed patients; Overinvestigation of iron overload in Asian Australians

Three lymphoma drugs up for PBS listing Three lymphoma therapies are to be considered at the July meeting of the  Pharmaceutical Benefits Advisory Committee. The Leukaemia Foundation says it will be providing consumer comments to support PBS listings for acalabrutinib (Calquence) patients with relapsed/refractory mantle cell lymphoma (MCL) who had received at least one prior therapy ...

Already a member?

Login to keep reading.

© 2021 the limbic